Volume 16, Number 11—November 2010
CME ACTIVITY - Research
Enhanced Surveillance of Coccidioidomycosis, Arizona, USA, 2007–2008
Table 3
Description | Mean | Median | Range | Interquartile range | Total |
---|---|---|---|---|---|
Days from symptom onset to diagnosis date, n = 422 | 209 | 55 | 0–10,280 | 22–143 | |
Days from first seeking health care to diagnosis date, n = 422 | 156 | 23 | 0–10,280 | 6–74 | |
Days of symptom duration,* n = 420 | 202 | 120 | 0–5,224 | 49–198 | |
Days missed from work,† n = 159 | 31 | 14 | 0–365 | 5–30 | |
Days missed from school,‡ n = 35 | 17 | 9 | 0–120 | 3–15 | |
Days unable to perform daily activities,§ n = 352 | 96 | 47 | 0–1,825 | 15–120 | |
Per visit hospital charges for coccidioidomycosis primary diagnoses, n = 1,093 | $54,000 | $33,000 | $113–$1,474,795 | $59 million | |
Per visit hospital charges for coccidioidomycosis primary or secondary diagnoses, n = 1,735 | $49,000 | $30,000 | $113–$1,474,795 | $86 million |
*Symptom duration analysis includes patients who had recovered and those who had not yet recovered from their symptoms at the time of interview.
†Number of days missed from work was available for 159/167 patients who reported that they missed work due to their disease.
‡Number of days missed from school was available for 35/37 patients who reported that they missed school due to their disease.
§Number of days patients were unable to perform daily activities was available for 352/369 patients who reported that their disease interfered with their daily activities.
Page created: September 07, 2011
Page updated: September 07, 2011
Page reviewed: September 07, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.